David Solit

Co-Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology · New York Presbyterian Hospital

Credentials: · · · ·

History

Marie-Josée & Henry R. Kravis Center for Molecular Oncology · New York Presbyterian Hospital
Present
Marie-Josée & Henry R. Kravis Center for Molecular Oncology · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present

SPORE in Bladder Cancer
National Cancer Institute · P50
PI · $2.5M · Sloan-Kettering Inst Can Research
2026–2031
HER2 PET Imaging to Assess HER2 Heterogeneity and Predict Response to HER2-Targeted Therapy in Biliary Tract Cancer
National Cancer Institute · R01
PI · $715K · Sloan-Kettering Inst Can Research
2026–2031
The Role of EP300 Mutations in Bladder Cancer Pathogenesis and Drug Response
National Cancer Institute · R01
Contact PI · $1.2M · Sloan-Kettering Inst Can Research
2025–2029
HER2 PET Imaging to Assess HER2 Heterogeneity and Predict Response to HER2-Targeted ADC Therapy in Urothelial Carcinoma
National Cancer Institute · R01
PI · $1.7M · Sloan-Kettering Inst Can Research
2024–2029

Genomic Profiling in Cancer Patients
Principal investigator · Recruiting
Memorial Sloan Kettering Cancer Center
2013–2027
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2004
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2004
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2003–2010